Smart Guide,is a cyclic peptide full agonist of melanocortin-4 receptor (MC4R

The setmelanotide peptide sequence represents a significant advancement in the treatment of specific genetic forms of obesity. This peptide therapeutic, also known by its investigational name RM-493, is a potent and selective agonist of the melanocortin-4 receptor (MC4R). Its efficacy lies in its precise amino acid composition and structure, which mimics endogenous melanocortin peptides to regulate appetite and energy expenditure. Understanding the setmelanotide peptide sequence is crucial for appreciating its mechanism of action and its therapeutic potential.

At its core, setmelanotide is an 8-amino acid cyclic peptide. The complete amino acid sequence is often documented as N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinyl-amide, or more concisely, Ac-Arg-Cys(1)-D-Ala-His-D-Phe-Arg-Trp-Cys(1)-NH2. This sequence is a modified analog of the endogenous melanocortin peptide alpha-melanocyte-stimulating hormone (α-MSH). The inclusion of D-amino acids (D-alanine and D-phenylalanine) and the cyclization through disulfide bonds between the two cysteine residues are key modifications that enhance its stability and potency. The setmelanotide peptide sequence is also sometimes represented by the partial sequence RCAHFRWC, which highlights a core functional motif.

The setmelanotide peptide sequence is designed to interact specifically with the melanocortin-4 receptor (MC4R). This receptor plays a pivotal role in the central regulation of energy homeostasis. When setmelanotide binds to MC4R, it activates the receptor, signaling the brain to reduce appetite and increase energy expenditure. This targeted action is particularly effective in individuals with genetic defects in the leptin-melanocortin pathway, such as those with pro-opiomelanocortin (POMC) deficiency or leptin receptor (LEPR) deficiency. In these conditions, the natural signaling pathway is impaired, leading to insatiable hunger and severe obesity. Setmelanotide acts as a pharmacological bypass, restoring proper signaling.

The sequence of between three and ten alpha-amino acids joined by peptide bonds is a general description that applies to many peptides, but the specific arrangement and modifications in setmelanotide are what confer its unique properties. Its ability to act as a selective melanocortin 4 receptor (MC4R) agonist is demonstrated by its low nanomolar EC50 values for both human and rat MC4R, typically around 0.27 nM and 0.28 nM, respectively. This high affinity and selectivity ensure that it primarily targets MC4R, minimizing off-target effects.

The development of setmelanotide has been a collaborative effort, with its discovery at Ipsen and subsequent development by Rhythm Pharmaceuticals. The drug, marketed as IMCIVREE®, was approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of obesity and control of hunger associated with POMC or LEPR deficiency in adults and children aged 2 years and older. Rhythm Pharmaceuticals has also been instrumental in launching IMCIVREE® (setmelanotide) in other regions, such as Germany, for similar indications.

Beyond its primary indication, research continues into the broader applications of setmelanotide. Studies have shown that treatment with setmelanotide led to weight loss in adolescents and adults with additional genetic obesity disorders, suggesting potential for use in a wider range of rare obesity conditions. The mechanism of action of setmelanotide is intrinsically linked to its ability to activate MC4R, thereby helping to reduce excess body weight and maintain weight reduction long term.

The setmelanotide peptide sequence can be further understood by examining its structural similarities and differences with endogenous melanocortins. While it shares a core motif with α-MSH, particularly the His-Phe-Arg-. Trp sequence, it is a cyclic 8-amino acid peptide that differs in several positions. These differences are crucial for its pharmacological profile. The sequence and structure of setmelanotide have been elucidated through various scientific techniques, including cryo-electron microscopy, which has provided detailed insights into its interaction with the MC4R-Gs-protein complex.

The development of peptide formulations for sustained release is also an area of research, aiming to improve patient convenience and therapeutic outcomes. While specific details on setmelanotide peptide sequence price or setmelanotide price are subject to market dynamics and regional availability, the cost reflects its specialized nature as a targeted therapy for rare genetic conditions. Information on setmelanotide peptide dosage would be determined by a healthcare professional based on the individual patient's needs and the specific indication.

In summary, the setmelanotide peptide sequence, **Ac-